Provided by Tiger Trade Technology Pte. Ltd.

CAR-T Concept

1,787.25
-19.0613-1.06%
Number of Gainers:- -
Number of Losers:2
Number of Flat:- -
PE:- -
High:1,799.37
Open:1,799.37
Low:1,770.43
Close:1,806.31
Volume:7.46M
Turnover:1.06B
Market Cap:460.73B
Float Cap:446.47B

Loading ...

Novartis announces two-year results from Phase III APPLAUSE-IgAN study

TIPRANKS
·
Mar 30

Gilead Sciences Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
Mar 28

Novartis to buy biotech company Excellergy for up to $2B

TIPRANKS
·
Mar 27

Novartis (NVS) Stock Rises on $2B Excellergy Acquisition to Expand Allergy Portfolio

TIPRANKS
·
Mar 27

Novartis to Acquire US Biotech Firm Excellergy in Deal Worth Up to $2 Billion

Deep News
·
Mar 27

Novartis's Excellergy Payments Should Be Back-End Loaded -- Market Talk

Dow Jones
·
Mar 27

Novartis Acquires Excellergy for $2 Billion to Strengthen Food Allergy and Immune Disorder Portfolio

Stock News
·
Mar 27

Novartis to Acquire Excellergy For Up to $2 Billion

MT Newswires Live
·
Mar 27

Galapagos FY2025 operating income rises to €295 million; revenue jumps 304% to €1.11 billion

Reuters
·
Mar 27

Novartis Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Mar 27

Novartis Ag : Morgan Stanley Raises Target Price to $170 From $143

THOMSON REUTERS
·
Mar 26

Clear Street says Gilead-Ouro deal highlights upside for Cullinan’s velinotamig

TIPRANKS
·
Mar 25

These Stocks Are Today's Movers: Apollo, Salesforce, Gartner, Estée Lauder, APA, Tesla, Intuit, and More -- Barrons.com

Dow Jones
·
Mar 25

Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday

MT Newswires Live
·
Mar 24

U.S. Stocks to Watch: Tesla, Jefferies, Apollo, Gilead, Estée Lauder, and More

Dow Jones
·
Mar 24

Deals of the day-Mergers and acquisitions

Reuters
·
Mar 24

PRESS DIGEST -Wall Street Journal - March 24

Reuters
·
Mar 24

Galapagos and Gilead discuss OM336 collaboration with 20%-23% royalties

Reuters
·
Mar 24

Gilead to acquire Ouro Medicines for $1.675B

TIPRANKS
·
Mar 24

Gilead - Currently in Advanced Talks With Galapagos With Respect to Potential Research and Development Collaboration on Acquired Ouro Medicines Assets

THOMSON REUTERS
·
Mar 24